Getein Biotech Inc Working Capital to Net Assets Ratio
Getein Biotech Inc working capital to net assets ratio. Getein Biotech Inc (603387) has a Working Capital to Net Assets ratio of 54.4% as of March 2026. Working capital of CN¥1.60 Billion (current assets of CN¥2.32 Billion minus current liabilities of CN¥722.36 Million) is measured against net assets of CN¥2.93 Billion. A higher ratio indicates strong short-term liquidity financed by the equity base. Check Getein Biotech Inc tangible equity quality to evaluate the tangible quality of the company's equity base.
WC/NA Ratio
Working Capital
Current Assets
Current Liabilities
Working Capital to Net Assets Ratio of Getein Biotech Inc (2012–2025)
Working capital to net assets ratio of Getein Biotech Inc from 2012 to 2025. This chart shows how Getein Biotech Inc's Working Capital to Net Assets ratio has evolved across 14 annual periods from 2012 to 2025. As of March 2026, the ratio stands at 54.4%, reflecting working capital of CN¥1.60 Billion against net assets of CN¥2.93 Billion CNY. See Getein Biotech Inc (603387) defensive interval to measure how many days the company can operate on defensive assets alone.
Getein Biotech Inc Working Capital to Net Assets Ratio by Year (2012–2025)
Getein Biotech Inc working capital to net assets ratio by year from 2012 to 2025. The table below presents the year-by-year Working Capital to Net Assets ratio for Getein Biotech Inc from 2012 to 2025, covering 14 annual filings. Each row shows current assets, current liabilities, working capital, net assets, the ratio, and the change in percentage points compared to the prior year. For the complete balance sheet picture, see Getein Biotech Inc asset portfolio.
| Year | WC/NA Ratio | Working Capital (CNY) | Net Assets | Current Assets | Current Liabilities | Change (pp) |
|---|---|---|---|---|---|---|
| 2025 | 50.6% | CN¥1.45 Billion | CN¥2.86 Billion | CN¥2.30 Billion | CN¥855.17 Million | ▲ +16.9 pp |
| 2024 | 33.7% | CN¥917.03 Million | CN¥2.72 Billion | CN¥1.86 Billion | CN¥940.01 Million | ▼ -9.1 pp |
| 2023 | 42.8% | CN¥1.17 Billion | CN¥2.74 Billion | CN¥2.15 Billion | CN¥977.86 Million | ▼ -11.3 pp |
| 2022 | 54.1% | CN¥1.44 Billion | CN¥2.66 Billion | CN¥2.40 Billion | CN¥958.06 Million | ▼ -14.2 pp |
| 2021 | 68.2% | CN¥1.55 Billion | CN¥2.27 Billion | CN¥2.37 Billion | CN¥813.48 Million | ▼ -4.6 pp |
| 2020 | 72.9% | CN¥1.46 Billion | CN¥2.00 Billion | CN¥2.12 Billion | CN¥656.61 Million | ▼ -1.5 pp |
| 2019 | 74.3% | CN¥1.25 Billion | CN¥1.68 Billion | CN¥1.57 Billion | CN¥316.88 Million | ▼ -5.4 pp |
| 2018 | 79.7% | CN¥1.10 Billion | CN¥1.38 Billion | CN¥1.28 Billion | CN¥180.00 Million | ▼ -2.1 pp |
| 2017 | 81.8% | CN¥939.13 Million | CN¥1.15 Billion | CN¥1.05 Billion | CN¥111.73 Million | ▲ +25.3 pp |
| 2016 | 56.5% | CN¥193.90 Million | CN¥342.96 Million | CN¥279.16 Million | CN¥85.26 Million | ▲ +3.2 pp |
| 2015 | 53.4% | CN¥143.35 Million | CN¥268.60 Million | CN¥197.78 Million | CN¥54.44 Million | ▲ +16.0 pp |
| 2014 | 37.3% | CN¥61.69 Million | CN¥165.19 Million | CN¥100.99 Million | CN¥39.30 Million | ▲ +19.0 pp |
| 2013 | 18.3% | CN¥15.41 Million | CN¥84.06 Million | CN¥85.31 Million | CN¥69.90 Million | ▲ +32.7 pp |
| 2012 | -14.4% | CN¥-5.85 Million | CN¥40.63 Million | CN¥43.07 Million | CN¥48.92 Million | — |